Technical Analysis for ATHX - Athersys, Inc.

Grade Last Price % Change Price Change
grade C 1.32 7.32% 0.09
ATHX closed up 7.32 percent on Friday, August 16, 2019, on 88 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical ATHX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Slingshot Bearish Bearish Swing Setup 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 7.32%
NR7 Range Contraction 7.32%
Oversold Stochastic Weakness 7.32%
1,2,3 Retracement Bearish Bearish Swing Setup 9.09%
180 Bearish Setup Bearish Swing Setup 9.09%

Older signals for ATHX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The company's lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase I clinical trials and is under two ongoing Phase II clinical trials for treating a range of diseases and various application in the field of clinical regenerative medicine. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing novel pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
Health Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Diseases Pharmaceuticals Diabetes Pharmacy Drug Discovery Clinical Trial Obesity Schizophrenia Inflammatory Bowel Disease Regenerative Medicine Cardiovascular Disease Design Of Experiments Pfizer Mesoblast Orthopedic Applications
Is ATHX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Aug 8 Athersys, Inc. 2019 Q2 - Results - Earnings Call Slides
Aug 8 Athersys (ATHX) Q2 2019 Earnings Call Transcript
Aug 8 42 Healthcare Stocks Moving In Wednesday's After-Market Session
Aug 8 Athersys, Inc. (ATHX) on Q2 2019 Results - Earnings Call Transcript
Aug 7 Athersys EPS beats by $0.03, beats on revenue
Aug 7 Athersys Reports Second Quarter 2019 Results
Jul 31 Do Institutions Own Shares In Athersys, Inc. (NASDAQ:ATHX)?
Jul 30 45 Healthcare Stocks Moving In Monday's After-Market Session
Jul 29 40 Healthcare Stocks Moving In Friday's After-Market Session
Jul 8 Athersys to Host Second Quarter Financial Results Call
See more ATHX news...
Indicators
Indicator Value
52 Week High 2.23
52 Week Low 1.2
Average Volume 597,252
200-Day Moving Average 1.6148
50-Day Moving Average 1.5238
20-Day Moving Average 1.351
10-Day Moving Average 1.276
Average True Range 0.0847
ADX 38.8
+DI 17.9808
-DI 21.7204
Chandelier Exit (Long, 3 ATRs ) 1.3259
Chandelier Exit (Short, 3 ATRs ) 1.4541
Upper Bollinger Band 1.5298
Lower Bollinger Band 1.1722
Percent B (%b) 0.41
BandWidth 26.469282
MACD Line -0.0813
MACD Signal Line -0.0816
MACD Histogram 0.0003
Fundamentals Value
Market Cap 150.36 Million
Num Shares 114 Million
EPS -0.26
Price-to-Earnings (P/E) Ratio -5.08
Price-to-Sales 61.05
Price-to-Book 8.00
PEG Ratio -0.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.50
Resistance 3 (R3) 1.50 1.43 1.47
Resistance 2 (R2) 1.43 1.39 1.44 1.46
Resistance 1 (R1) 1.38 1.36 1.41 1.38 1.45
Pivot Point 1.31 1.31 1.33 1.32 1.31
Support 1 (S1) 1.26 1.27 1.29 1.26 1.19
Support 2 (S2) 1.19 1.24 1.20 1.18
Support 3 (S3) 1.14 1.19 1.17
Support 4 (S4) 1.14